Agios Pharmaceuticals (NASDAQ:AGIO) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

A number of other research analysts have also weighed in on AGIO. JPMorgan Chase & Co. raised their target price on shares of Agios Pharmaceuticals from $20.00 to $25.00 and gave the company a “neutral” rating in a report on Tuesday, January 6th. Leerink Partners upped their price target on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, December 26th. Truist Financial increased their price objective on shares of Agios Pharmaceuticals from $32.00 to $38.00 and gave the company a “buy” rating in a research report on Wednesday, December 24th. Royal Bank Of Canada cut shares of Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their price objective for the stock from $57.00 to $28.00 in a research note on Wednesday, November 19th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Monday, December 29th. Six analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $40.67.

Agios Pharmaceuticals Trading Up 3.6%

Shares of Agios Pharmaceuticals stock opened at $28.84 on Friday. The stock has a 50 day moving average of $28.17 and a 200 day moving average of $32.79. Agios Pharmaceuticals has a 12 month low of $22.24 and a 12 month high of $46.00. The firm has a market cap of $1.69 billion, a PE ratio of -4.06 and a beta of 0.89.

Insider Activity at Agios Pharmaceuticals

In related news, insider Krishnan Viswanadhan sold 2,959 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $27.80, for a total transaction of $82,260.20. Following the transaction, the insider directly owned 5,141 shares in the company, valued at approximately $142,919.80. This represents a 36.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Tsveta Milanova sold 2,932 shares of the company’s stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88. Following the transaction, the insider owned 29,190 shares in the company, valued at $790,757.10. The trade was a 9.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 36,262 shares of company stock valued at $984,237 over the last three months. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Creative Planning raised its holdings in shares of Agios Pharmaceuticals by 2.2% in the third quarter. Creative Planning now owns 13,119 shares of the biopharmaceutical company’s stock worth $527,000 after buying an additional 280 shares during the period. Assetmark Inc. lifted its stake in shares of Agios Pharmaceuticals by 37.9% during the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 362 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Agios Pharmaceuticals by 0.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company’s stock valued at $4,393,000 after acquiring an additional 512 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Agios Pharmaceuticals by 26.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,834 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 588 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH grew its position in Agios Pharmaceuticals by 1.2% in the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 55,284 shares of the biopharmaceutical company’s stock valued at $1,839,000 after acquiring an additional 633 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.